Involvement of nitric oxide pathways in neurogenic pulmonary edema induced by vagotomy by BLANCO, Eleonora et al.
BASIC RESEARCH
Involvement of nitric oxide pathways in neurogenic
pulmonary edema induced by vagotomy
Eleonora Blanco,I Marli Martins-Pinge,I Elizabeth Oliveira-Sales,II Cristiane BusnardoIII
IPhysiological Sciences, Universidade Estadual de Londrina, Campus Universita´rio Londrina, Londrina, Parana´, Brazil. IIFederal University of Sa˜o Paulo
(UNIFESP), Sa˜o Paulo/SP, Brazil. IIIUniversity of Sa˜o Paulo (USP), Ribeira˜o Preto/SP, Brazil.
OBJECTIVE: The objective of this study was to evaluate the involvement of peripheral nitric oxide (NO) in vagotomy-
induced pulmonary edema by verifying whether the nitric oxide synthases (NOS), constitutive (cNOS) and inducible
(iNOS), participate in this mechanism.
INTRODUCTION: It has been proposed that vagotomy induces neurogenic pulmonary edema or intensifies the
edema of other etiologies.
METHODS: Control and vagotomized rats were pretreated with 0.3 mg/kg, 3.0 mg/kg or 39.0 mg/kg of L-NAME, or
with 5.0 mg/kg, 10.0 mg/kg or 20.0 mg/kg of aminoguanidine. All animals were observed for 120 minutes. After the
animals’ death, the trachea was catheterized in order to observe tracheal fluid and to classify the severity of
pulmonary edema. The lungs were removed and weighed to evaluate pulmonary weight gain and edema index.
RESULTS: Vagotomy promoted pulmonary edema as edema was significantly higher than in the control. This effect
was modified by treatment with L-NAME. The highest dose, 39.0 mg/kg, reduced the edema and prolonged the
survival of the animals, while at the lowest dose, 0.3 mg/kg, the edema and reduced survival rates were maintained.
Aminoguanidine, regardless of the dose inhibited the development of the edema. Its effect was similar to that
observed when the highest dose of L-NAME was administered. It may be that the non-selective blockade of cNOS by
the highest dose of L-NAME also inhibited the iNOS pathway.
CONCLUSION: Our data suggest that iNOS could be directly involved in pulmonary edema induced by vagotomy and
cNOS appears to participate as a protector mechanism.
KEYWORDS: Pulmonary Weight; Nitric oxide synthase; L-NAME; Aminoguanidine; Edema Index.
Blanco E, Martins-Pinge M, Oliveira-Sales E, Busnardo C. Involvement of nitric oxide pathways in neurogenic pulmonary edema induced by
vagotomy. Clinics. 2011;66(6):1061-1066.
Received for publication on February 17, 2011; First review completed on February 24, 2011; Accepted for publication on March 4, 2011
E-mail: lafispulmonar@uel.br
Tel.: 55 43 33714307
INTRODUCTION
Neurogenic pulmonary edema (NPE) is a fatal complica-
tion of severe insults to the central nervous system.1,2 It is
proposed that neurogenic pulmonary edema is a functional
disturbance provoked by adverse stimuli from outside the
lungs and that in the rat, the pulmonary afferent fiber is
essential to the production of this edema.3 Autonomic
nervous dysfunction, possibly sympathetic nerve over-
excitation or vagus nerve dysfunction by vagotomy or by
lesion of vagal nuclei in the medulla, has been show to
induce NPE.2 Studies involving NPE by intracisternal
injection of fibrinogen and thrombin have indicated that
bilateral vagotomy or the treatment with atropine increased
the severity of the edema.4 Vagotomy increases the amount
of edema for a given degree of pulmonary hypertension.5
Vagotomy-induced pulmonary edema has been discussed
as neurogenic pulmonary edema. The lungs of vagotomized
rats showed alveolar edema.6 Blood volume and hematocrit
reading became considerably reduced during the develop-
ment of acute pulmonary edema caused by bilateral cervical
vagotomy, depending on whether pulmonary hemorrhage
occurs as a complication of the edema and congestion.7
Since 1966, it has been proposed that bilateral interruption
of afferent impulses of the tenth cranial nerve is the factor
that initiates vagotomy-induced lung edema.8 A subsequent
observation concluded that vagal capsaicin-sensitive nerves
wielded an inhibitory effect on the development of fibrin
injection into the cisterna magna-induced pulmonary
edema.9 It was proposed that an unknown neurotransmitter
released from capsaicin-sensitive nerves may participate in
increasing the lung vascular permeability caused by
sympathetic nerve stimulation and that norepinephrine
may also play a role in the regulation of permeability
through alpha- and beta-adrenoceptors.10
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It has been recognized that the main site of nitric oxide
(NO) production in the circulatory system is in the lungs.11
NO is produced by a group of enzymes known as nitric
oxide synthases (NOS). These enzymes convert L-arginine
into NO and L-citruline. Three isoforms of NOS have been
identified, including two constitutive forms: neuronal
(nNOS) and endothelial (eNOS), and an inducible form
(iNOS). NO is a potent vasodilator in bronchial circulation
and may play an important role in regulating airway blood
flow. It also modulates vascular tone through its vasodila-
tory properties. Excess amounts of NO may cause hypoten-
sion associated with sepsis, and decreased NO levels within
the lungs may contribute to the pathologic states associated
with pulmonary hypertension. NO may also play a critical
role in ventilation-perfusion coupling in the lung. This
theory is supported by the fact that endogenous NO levels
in the lung change rapidly in direct proportion to inspired
oxygen.12
NO has been related to pulmonary edema of various
etiologies. Pulmonary exhaled NO was lower in mountai-
neers prone to high-altitude pulmonary edema than in those
resistant to this condition.13,14 Reduced exhaled NO may be
as a result of altered pulmonary NO synthesis and/or
transport and clearance, in line with the hypothesis that, in
these subjects, a defect in pulmonary epithelial NO
synthesis may contribute to exaggerated hypoxic pulmon-
ary vasoconstriction and, in turn, to pulmonary edema.13 It
was also observed that susceptible subjects have decreased
nitrate-nitrite concentrations in bronchoalveolar fluid at
high altitude, while resistant subjects have increased
concentrations, further supporting a critical role for endo-
genous NO production in maintaining lower pulmonary
vascular resistance.15 L-Arginine, a NO synthase substrate,
and N-nitro-L-arginine (L-NNA), a NO synthase inhibitor,
prevented and aggravated, respectively, the increase in
pulmonary vascular permeability induced by radiologic
contrast medium at high doses, in rats.16 Pretreatment with
NOS inhibitors, such as N-nitro-L-arginine methyl ester (L-
NAME), aminoguanidine and dexamethasone, significantly
reduced endotoxin-induced pulmonary edema. Over-
production of NO was considered detrimental to the lung
and exerted toxic effects on the pulmonary endothelial
layer.11 However, the involvement of NO in NPE has not yet
been evaluated.
The main objective of this study was to evaluate the
involvement of peripheric NO and its enzymatic production
in rats with vagotomy-induced pulmonary edema, by
assessing the participation of the cNOS and iNOS pathways
in this mechanism. To this end, some animals were
pretreated with L-NAME, a cNOS inhibitor, and others
with aminoguanidine, a relatively specific iNOS inhibitor.
MATERIALS AND METHODS
Animals and experimental groups
Experimental protocols were performed in accordance
with the Guide for the Care and Use of Laboratory Animals
and the Ethical Principles for Animal Experimentation,
established by the Brazilian Committee for Animal
Experimentation (COBEA), and in accordance with the
animal experimentation Ethics Committee of the State
University of Londrina (CEEA/UEL).
Adult male Wistar rats (n = 167), weighing 250–320 g,
were distributed into 14 groups: C—control animals (n = 14);
V—vagotomized animals (n = 14); CL 0.3 (n = 11); CL 3.0
(n = 11); CL 39 (n = 11)—control animals pretreated with
0.3 mg/kg, 3.0 mg/kg or 39.0 mg/kg L-NAME, respec-
tively; VL 0.3 (n = 14); VL 3.0 (n = 9); VL 39 (n = 8)—
vagotomized animals pretreated with 0.3 mg/kg, 3.0 mg/
kg or 39.0 mg/kg L-NAME, respectively; CA 5 (n = 11); CA
10 (n= 11); CA 20 (n= 11)—control animals pretreated with
5.0 mg/kg, 10.0 mg/kg or 20.0 mg/kg aminoguanidine,
respectively; VA 5 (n= 14); VA 10 (n = 14); VA 20 (n= 14)—
vagotomized animals pretreated with 5.0 mg/kg, 10.0 mg/
kg or 20.0 mg/kg aminoguanidine, respectively.
Treatment with nitric oxide synthase (NOS)
inhibitors
Pretreatment consisted of an intravenous injection of L-
NAME or aminoguanidine 10 minutes before surgery.
Untreated control and vagotomized animals received an
equivalent volume of saline. All animals were anesthetized
by inhalation of ethyl ether.
The drugs utilized in this study were: N(G)-nitro-L-
arginine methyl ester, L-NAME (RBI) and aminoguanidine
(Sigma Co., St Louis, MO, USA).
Vagotomy
In controls and vagotomized rats, the vagus nerve was
exposed through a midline incision in the neck. The vagus
nerve was identified and separated from the common
carotid artery. In vagotomized animals, the vagus nerve was
severed bilaterally. After recovering from surgery, all
animals were observed for 120 minutes. Those that died
during this period were noted, along with their time of
death. Survivors were sacrificed, under ether anesthesia by
severing the inferior vena cava and draining the blood.
After the animals’ death, the trachea was cannulated in
order to observe tracheal fluid and to classify the severity of
pulmonary edema. By way of thoracic incision, lungs were
removed and weighed to evaluate pulmonary weight gain
and edema index.
Pulmonary edema evaluation
The severity of pulmonary edema was graded by a
method proposed by Hamdy et al., with modifications.17
The edema was graded from 0 to 2, according to the
presence of fluid in the trachea, with 0 for none and 2 for
severe. When edema fluid spontaneously appeared in the
tracheal tube after opening the chest, the edema was
classified as grade 2. If fluid appeared in the tracheal tube
only when the lungs were gently pressed, the edema was
grade 1. When edema fluid did not appear at all, even under
gentle pressure, the grade was 0.
The lungs were weighed to obtain the weight gain caused
by pulmonary edema. As previously proposed, edema was
evaluated from the ratio of pulmonary weight:body weight
(100xPW/BW); this ratio is still in use as the edema index.18
Statistical analysis
Differences between means and the SE were examined for
significance by ANOVA, followed by Tukeys Multiple
Comparison Test. Survival time was examined by
Student’s t-test, comparing each pair of control to vagoto-
mized animals, vagotomized to vagotomized pretreated
with drugs and the pairs of control and vagotomized
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animals pretreated with drugs. Survival time was displayed
in curves.
RESULTS
Our data showed that vagotomy promoted the develop-
ment of pulmonary edema, as, in the vagotomized rats, the
pulmonary weight (g) (2.60¡0.31) and edema index
(0.94¡0.10) were higher than the pulmonary weight (g)
(1.50¡0.06) and edema index (0.54¡0.01) of the control
animals (Figures 1 and 2). Among vagotomized rats (n = 14),
four animals died during the experimental period (Figure 3)
and five animals developed grade 2 edema (Tables 1 and 2).
The effects observed in vagotomized animals pretreated
with L-NAME varied according to the dose (Figure 1). The
highest dose, 39 mg/kg, reduced the edema index
(0.58¡0.02) and no animal in the group VL39 suffered
edema grade 2 (Table 1). On the other hand, at the lowest
dose, 0.3 mg/kg, the pulmonary weight (g) (2.97¡0.28) and
edema index (1.00¡0.10) remained high and, out of the 14
animals in the group VL0.3, 6 had edema grade 2 (Table 1).
The dose of 3.0 mg/kg promoted intermediate effects
between the other two doses (Figure 1). Treatment with
39 mg/kg also prolonged the survival of the animals while,
in the group pretreated with 0.3 mg/kg L-NAME, eight rats
died during the observation period (Figure 3A).
The results observed in control animals treated with L-
NAME or with aminoguanidine were similar to those in the
control animals without treatment. All three doses of
aminoguanidine treatment reduced the pulmonary weight,
the edema index and the edema grade in vagotomized rats
(Figure 2 and Table 2).
DISCUSSION
The objective of the present study was to assess the
involvement of NO pathways in the development of
pulmonary edema. It was observed that the largest dose of
L-NAME inhibited the development of pulmonary edema
induced by vagotomy in the group VL39 and prolonged the
survival of those animals, while the smallest dose did not
promote the same effects. On the other hand, treatment with
aminoguanidine, regardless of the dose administered,
inhibited the development of the edema. Our data suggest
that NO production from iNOS is involved in the
pulmonary edema induced by vagotomy and, on the
contrary, NO derived by cNOS seems to have protective
effects against this type of edema.
In rats, the vagus nerve and the sympathetic trunk are
anatomically adjacent. Hence, in the vagotomy performed in
the present study, the sympathetic branch could be
damaged, too. In early studies of pulmonary edema
following vagotomy it was shown that when the midcervi-
cal vagosympathetic trunk in guinea pigs was severed,
bilateral interruption of afferent impulses of the tenth
cranial nerve was the factor that initiated lung edema.8
This edema was developed in artificially ventilated guinea
pig,19 and tracheotomy had no demonstrable effect in
Figure 1 -Mean and individual values of (A) pulmonary weight (g) and (B) edema index. Controls or vagotomized rats pretreated with
saline (C and V) or with 0.3 mg/kg (CL 0.3 and VL 0.3), 3.0 mg/kg (CL 3.0 and VL3.0), or 39 mg/kg (CL 39 and VL 39) L-NAME. * Statistically
different from its pair control (p,0.01), { statistically different from vagotomized (p,0.05), { statistically different from VL 39 (p,0.01).
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vagotomized rats submitted to moderate pulmonary con-
gestion.7 The observation that edema induced by fibrinogen
and thrombin was increased by bilateral vagotomy, or by
treatment with atropine, indicates that efferent cholinergic
fibers in the vagus nerve may play a role in lowering the
severity of pulmonary edema.4 In a subsequent experiment
Figure 2 -Mean and individual values of (A) pulmonary weight (g) and (B) edema index. Controls or vagotomized rats pretreated with
saline (C and V) or with 5 mg/kg (CA 5 and VA 5), 10 mg/kg (CA 10 and VA 10) or 20 mg/kg (CA 20 and VA 20) aminoguanidine.
{ statistically different from vagotomized (p,0.01), {statistically different from control group (p,0.001), 1 statistically different from
vagotomized (p,0.001).
Figure 3 - (A) Survival curve of controls (C), vagotomized rats (V) or rats pretreated with 0.3 mg/kg (CL 0.3and VL 0.3), 3.0 mg/kg (CL 3.0
andVL3.0) or 39 mg/kg (CL39 and VL 39) L-NAME . (B) Survival curve of controls (C), vagotomized rats (V) or rats pretreated with 5 mg/
kg (CA 5 and VA 5), 10 mg/kg (CA 10 and VA 10) or 20 mg/kg (CA 20 and VA 20) aminoguanidine. The upper horizontal line represents
100% survival during the period of observation (120 minutes). On the other lines, each drop is equivalent to the death of one animal.
*Statistically different from control group (p,0.05), { statistically different from VL 39 (p,0.05).
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involving the use of capsaicin, it was observed that afferent
vagal impulses could exert an inhibitory effect on the
development of fibrin-induced NPE.9 Moreover, it was
observed that pretreatment with atropine attenuated pul-
monary edema in spinal cord-injured rats.20 A hypothesis
was introduced that early administration of high atropine
doses can prevent NPE development on the basis of the
attenuation of heart rate decrease, which was recognized as
an important factor of neurogenic pulmonary edema
formation.21 In rats, bilateral vagotomy increased the
incidence of NPE.17 The rats that suffered vagotomy in
our study developed a higher pulmonary edema index than
the controls.
Among vagotomized rats, five animals showed edema
grade 2, and two had edema grade 1. Similar results were
observed in rats treated with a dose of 0.3 mg/kg of L-
NAME, which had a high edema index. Although these
results represent development of edema, not all animals
showed a degree of edema. In our opinion, this is because of
the fact that the rats were observed for a period of only 120
minutes and not until death, when more animals would
possibly have developed edema. The establishment of an
observation period followed by sacrifice of those who
survived could also justify the degree of variance observed
in the results presented.
The incidence of pulmonary edema in rats promoted by
intracisternal injection of fibrinogen and thrombin asso-
ciated with vagotomy was related to the high (25 mg/kg or
50 mg/kg) doses of pentobarbital anesthesia.4 It was later
observed that neurogenic pulmonary edema in rats was
more pronounced in pentobarbital-anesthetized (60 mg/kg)
rats compared with xylazine-ketamine anesthesia22 and that
it developed in rats anesthetized with 1.5% isoflurane, but
not in those anesthetized with 3% isoflurane,20 illustrating
that anesthetic drugs used in experimental neurogenic
pulmonary edema may be an important factor in the genesis
of edema. In the present study, all animals were anaes-
thetized by ether. However, the influence of anesthetic was
not evaluated or compared.
NPE has been also associated with pulmonary vascular
permeability.17 Concerning the mechanism of involvement
of NO in the maintenance of liquid balance in isolated rabbit
lung, it was found that inhibition of NO production with L-
NAME caused a significant increase in the rate of weight
gain, while the addition of lodoxamide or 8 Br-cGMP
attenuated this increase.23 These findings suggest a role for
endogenous NO in the relaxation of endothelial cells and
also in helping to prevent pulmonary edema by stabilizing
mast cells.
Thus, NO production mediated by iNOS has been
considered to exert a toxic effect on the pulmonary
endothelial layer once L-NAME (10 mg/kg), aminoguani-
dine (15 mg/kg) or dexamethasone (3 mg/kg) all attenuated
endotoxin-induced pulmonary edema.11 As iNOS has been
implicated in the pathophysiology of congestive heart
failure, it was hypothesized that iNOS deficiency would
reduce the severity of congestive heart failure in mice.
However, it was found that deficiency of iNOS did not
significantly affect severe congestive heart failure in mice
after myocardial infarction.24 According to the proposed
involvement of NO produced by iNOS mediation on
pulmonary edema, it was suggested that morphine had a
prophylactic effect on a-naphthylthiourea-induced lung
damage through inhibition of iNOS expression.18 The
results observed in the present study demonstrate that the
inhibition of NO production through iNOS promoted an
attenuation of vagotomy-induced pulmonary edema. Thus,
it is likely that, in this experimental model, NO produced by
iNOS is involved in the development of pulmonary edema.
Our group observed a similar result where pulmonary
edema induced by endotoxemia was attenuated by amino-
guanidine and worsened by L-NAME in control and
exercise-trained animals.25
L-NAME increases weight gain in isolated perfused
rabbit lung. The authors suggested that NO had a protective
role in the maintenance of normal pulmonary vascular
permeability.23 Moreover, it was observed that up-regula-
tion of eNOS is a protective mechanism against inflamma-
tory pulmonary damage following ischemia reperfusion.26
Also, the role of NO in the development of NPE in spinal
cord-injured rats was considered protective considering that
acute treatment with L-NAME (30 mg/kg) just before the
injury enhanced NPE severity.20 However, no data in the
literature has studied the involvement of both pathways of
NO production in neurogenic pulmonary edema.
L-NAME was considered an inhibitor of cNOS, however,
it may also inhibit iNOS at a dose of 10 mg/kg.11,27 The
treatment of vagotomized rats with 39 mg/kg of L-NAME
Table 1 - Incidence of edema grade of controls (C),
vagotomized (V) animals and controls or vagotomized
animals pretreated with 39 mg/kg (CL 39 and VL 39),
3.0 mg/kg (CL 3.0 andVL3.0) or 0.3 mg/kg (Cl 0.3 and VL
0.3) of L-NAME.
Edema Grade
0 1 2
Controls (n = 14) 14 0 0
Vagotomized (n = 14) 7 2 5*
CL 39 mg/kg (n= 11) 11 0 0
VL39 mg/kg (n = 8) 6 2 0
CL 3.0 mg/kg (n= 11) 11 0 0
VL 3.0 mg/kg (n= 9) 4 3 2
CL 0.3 mg/kg (n= 11) 11 0 0
VL 0.3 mg/kg (n= 14) 5 3 6** {
*Statistically different from control group (p,0.01),
**statistically different from its pair control group (p,0.001),
{statistically different from VL 39 (p,0.05).
Table 2 - Incidence of edema grade of controls (C),
vagotomized (V) animals and controls or vagotomized
animals pretreated with 20 mg/kg (CA 20 and VA 20),
10 mg/kg (CA 10 and VA 10) or 5 mg/kg (CA 5 and VA 5)
of aminoguanidine.
Edema Grade
0 1 2
Controls (n = 14) 14 0 0
Vagotomized (n= 14) 7 2 5*
CA 20 mg/kg (n= 11) 11 0 0
VA 20 mg/kg (n= 14) 13 0 1{
CA 10 mg/kg (n= 11) 11 0 0
VA 10 mg/kg (n= 14) 13 1 0{
CA 5 mg/kg (n= 11) 11 0 0
VA 5 mg/kg (n= 14) 13 1 0{
*Statistically different from control group (p,0.001);
{statistically different from vagotomized (p,0.001).
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promoted a reduction in pulmonary edema, that was
statistically different when compared with the group treated
with 0.3 mg/kg of L-NAME, and the treatment with
aminoguanidine (at any dose) reduced the incidence of
pulmonary edema in vagotomized rats, as well as in the
animals treated with the highest dose of L-NAME. Our
hypothesis is that the non-selective blockade of cNOS by
administering the highest dose of L-NAME could also
inhibit the iNOS pathway. Thus, cNOS appears to partici-
pate in the mechanism of pulmonary edema induced by
vagotomy, as a protective mechanism. On the other hand,
iNOS seems to be directly involved in pulmonary edema
induced by vagotomy.
REFERENCES
1. Liu S, Kuo HP, Sheppard MN, Barnes PJ, Evans TW. Vagal stimulation
induces increased pulmonary vascular permeability in guinea pig.
Am J Respir Crit Care Med. 1994;149:744-50.
2. Malik AB. Mechanisms of neurogenic pulmonary edema. Circ Res.
1985;57:1-18.
3. Lavasseur JE, Patterson JL, Garcia CI, Moskowitz MA, Choi SC, Kontos
HA. Effect of neonatal capsaicin treatment on neurogenic pulmonary
edema from fluid-percussion brain injury in the adult rat. J Neurosurg.
1993;78:610-8, doi: 10.3171/jns.1993.78.4.0610.
4. Ishikawa N, Kainuna M, Furuta T, Sato Y. Factors influencing fibrin-
induced pulmonary edema. Jpn J Pharmacol. 1988;46:255-60, doi: 10.
1254/jjp.46.255.
5. Bosso FJ, Lang SA, Maron MB. Role of hemodynamics and vagus nerve
in development of fibrin-induced pulmonary edema. J Appl Physiol.
1990;69:2227-32.
6. Cheon YH, Pae HH, Yoon AR, Lee JH, Baik TK. Modulation of alveolar
surfactant after lower cervical vagotomy. Korean J Anat. 2006;39:407-15.
7. Farber S. Neuropathic pulmonary edema. Further observations. Arch
Pathol. 1940;30:180-97.
8. Rech RH. The fiber component of the midcervical vagus nerve
implicated in vagotomy-induced lung edema. Exp Neurol. 1966;14:475-
83, doi: 10.1016/0014-4886(66)90131-2.
9. Hashiba Y, Ishikawa N, Sumita T, Takagi K, Hidaka H, Satake T.
Capsaicin-sensitive nerves exert an inhibitory effect on the development
of fibrin-induced pulmonary edema in rats. Am Rev Respir Dis.
1989;140:652-8.
10. Sakakibara H, Hashiba Y, Taki K, Kawanishi M, Shimada Y, Ishikawa N.
Effects of sympathetic nerve stimulation on lung vascular permeability
in the rat. Am Rev Respir Dis. 1992;145:685-92.
11. Lee RP, Wang D, Kao SJ, Chen HI. The lung is the major site that
produces nitric oxide to induce acute pulmonary oedema in endotoxin
shock. Clin Exp Pharmacol Physiol. 2001;28:315-20, doi: 10.1046/j.1440-
1681.2001.03446.x.
12. Dweik RA. The promise and reality of nitric oxide in the diagnosis and
treatment of lung disease. Cleveland Clin J Med. 2001;68:486-93, doi: 10.
3949/ccjm.68.6.486.
13. Duplain H, Sartori C, Lepori M, Egli M, Allemann Y, Nicod P, et al.
Exhaled nitric oxide in high-altitude pulmonary edema. Am J Respir Crit
Care Med. 2000;162:221-4.
14. Busch T, Ba¨rtsch P, Pappert D, Gru¨nig E, Hildebrandt W, Elser H, et al.
Hypoxia decreases exhaled nitric oxide in mountaineers susceptible to
high-altitude pulmonary edema. Am J Respir Crit Care Med.
2001;163:368-73.
15. Swenson ER, Maggiorini M, Mongovin S, Gibbs JS, Greve I, Mairba¨url H,
et al. Pathogenesis of high-altitude pulmonary edema. JAMA.
2002;287:2228-35, doi: 10.1001/jama.287.17.2228.
16. Sendo T, Kataoka Y, Takeda Y, Furuta W, Oishi R. Nitric oxide protects
against contrast media-increased pulmonary vascular permeability in
rats. Invest Radiol. 2000;35:472-8, doi: 10.1097/00004424-200008000-
00003.
17. Hamdy O, Maekawa H, Shimada Y, Feng GG, Ishikawa N. Role of
central nervous system nitric oxide in the development of neurogenic
pulmonary edema in rats. Crit Care Med. 2001;29:1222-8, doi: 10.1097/
00003246-200106000-00028.
18. Comert M, Sipahi EY, Ustun H, Isikdemir F, Numanoglu G, Barut F, et al.
Morphine modulates inducible nitric oxide synthase expression and reduces
pulmonary oedema induced by a-naphthylthiourea. Eur J Pharmacol.
2005;511:183-9, doi: 10.1016/j.ejphar.2005.01.038.
19. Borison HL, Kovacs BA. Central mechanisms in pulmonary oedema of
nervous origin in guinea-pigs. J Physiol. 1959;145:374-83.
20. Sedy J, Zicha J, Kunes J, Hejcl A, Sykova´ E. The role of nitric oxide in the
development of neurogenic pulmonary edema in spinal cord-injured
rats: the effect of preventive interventions. Am J Physiol Regul Integr
Comp Physiol. 2009;297:1111-7, doi: 10.1152/ajpregu.00251.2009.
21. Sedy´ J, Zicha J. Kunes J, Sykova´ E. Atropine may prevent the
development of neurogenic pulmonary edema. Med Hypotheses.
2009;73:42-4, doi: 10.1016/j.mehy.2008.12.051.
22. Leal Filho MB, Morandin RC, Almeida AR, Cambiucci EC, Borges G,
Gontijo JAR, et al. Importance of anesthesia for the genesis of neurogenic
pulmonary edema in spinal cord injury. Neurosci Lett. 2005;373:165-70,
doi: 10.1016/j.neulet.2004.10.019.
23. Mundy AL, Dorrington KL. Inhibition of nitric oxide synthesis augments
pulmonary oedema in isolated perfused rabbit lung. Br J Anaesth
2000;85:570-6, doi: 10.1093/bja/85.4.570.
24. Jones SP, Greer JJ, Ware PD, Yang J, Walsh K, Lefer DJ. Deficiency of
iNOS does not attenuate severe congestive heart failure in mice. Am J.
Physiol Heart Circ Physiol. 2005; 288: 365-70, doi: 10.1152/ajpheart.
00245.2004.
25. Mehanna A, Vitorino DC, Panis C, Blanco EEA, Pinge-Filho P, Martins-
Pinge MC. Cardiovascular and pulmonary effects of NOS inhibition in
endotoxemic conscious rats subjected to swimming training. Life Sci.
2007;81:1301-8, doi: 10.1016/j.lfs.2007.09.006.
26. Kaminski A, Pohl CB, Sponholz C, Ma N, Stamm C, Vollmar B, et al. Up-
regulation of endothelial nitric oxide synthase inhibits pulmonary
leukocyte migration following lung ischemia-reperfusion in mice.
Am J Pathol. 2004;164:2241-9, doi: 10.1016/S0002-9440(10)63780-7.
27. Wang D, Wei J, Hsu K, Jau JC, Lieu MW, Chao TJ, et al. Effects of nitric
oxide synthase inhibitors on systemic hypotension, cytokines and
inducible nitric oxide synthase expression and lung injury following
endotoxin administration in rats. J Biomed Sci. 1999;6:28-35, doi: 10.
1007/BF02256421.
NO pathways in neurogenic pulmonary edema
Blanco E et al.
CLINICS 2011;66(6):1061-1066
1066
